A little less than a year after it lost its partner for its preclinical hepatitis C therapy RG-101, Regulus Therapeutics announced last week that AstraZeneca has stepped away from the companies' program to develop an atherosclerosis drug targeting microRNA-33.

The firms will, however, continue to work together on drugs for metabolic diseases and cancer, and AstraZeneca retains the right to substitute a new target in lieu of miR-33 under their ongoing alliance.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.